Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CSF vs AraC + G-CSF Mobilization in MM
NCT01908621Phase 3Completed
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- Mar 2013
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cytarabine in multiple myeloma (MM) (2 arms), sponsored by Maria Skłodowska-Curie National Research Institute of Oncology. Primary endpoint: Proportion of patients with stem cell yield at least 5 × 10^6 CD34+ cells/kg. Started Mar 2013; status: completed.
02
Drugs
cytarabine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01908621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01908621.